Natera, Inc. (NASDAQ:NTRA) Insider Sells $377,010.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 3,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $125.67, for a total transaction of $377,010.00. Following the transaction, the insider now owns 57,432 shares of the company’s stock, valued at $7,217,479.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jonathan Sheena also recently made the following trade(s):

• On Wednesday, September 18th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $127.57, for a total value of $344,439.00.
• On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00.
• On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $113.82, for a total value of $307,314.00.

Natera Price Performance

NTRA opened at $129.84 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock’s 50 day simple moving average is $118.35 and its 200 day simple moving average is $107.98. The firm has a market cap of $15.94 billion, a price-to-earnings ratio of -41.62 and a beta of 1.53. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $132.01.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the prior year, the firm posted ($0.97) earnings per share. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. As a group, analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 target price on shares of Natera in a research note on Friday, September 13th. TD Cowen raised their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group upped their target price on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Robert W. Baird lifted their price target on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $120.07.

Institutional Investors Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. purchased a new stake in shares of Natera during the second quarter worth about $28,000. Quarry LP lifted its holdings in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the last quarter. YHB Investment Advisors Inc. purchased a new position in shares of Natera during the first quarter valued at approximately $36,000. Finally, Tobam bought a new position in shares of Natera during the second quarter valued at approximately $74,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.